Takeda To Assume Development Costs Of Synthetic ESA Product Hematide
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a $535 mil. deal, the Japanese firm will collaborate with Affymex on U.S. development of Hematide and solely pursue global development.